Organogenesis Holdings Inc.

What they do

Organogenesis develops, manufactures, and sells regenerative medicine products for chronic and acute wounds and for surgical and sports medicine applications. Its portfolio includes Apligraf, Dermagraft, PuraPly, CYGNUS Matrix, Affinity, NuShield, and AmchoThick. It sells through a direct sales force and independent agencies to hospitals, wound care centers, and physician offices.

Revenue drivers

• Advanced Wound Care — Primary segment, generating $36.1M in Q2 2026 (61% decline YoY). Products treat diabetic foot ulcers, venous leg ulcers, and other chronic wounds.
• Surgical & Sports Medicine — Smaller segment with $6.7M in Q2 2026 (18% decline YoY). Products used in soft tissue repairs and surgical wound management.

Recent performance

Q2 2026 net revenue was $42.8M, down 58% YoY from $100.8M, driven by a 61% drop in Advanced Wound Care sales. Net loss widened to $96.3M (($0.77) per share) from $9.4M loss a year ago. Adjusted EBITDA loss was $34.4M vs. $3.6M loss in Q2 2025. Gross margin fell to 45% from 73%.

Strategy

Management is focusing on evidence-based clinical efficacy to gain share as the market resets. They cite expanding share despite the contraction and continue advancing the ReNu program to unlock new markets. The company emphasizes its data and regulatory approvals (PMA/510(k)) as competitive advantages. It also suspended Dermagraft manufacturing pending a facility transition to Smithfield, RI.

Risks

• Medicare LCD uncertainty — Multiple delays and withdrawals of local coverage determinations for skin substitutes create ongoing reimbursement risk for key wound care products.
• Revenue concentration and decline — Advanced Wound Care revenue fell 61% in Q2 2026, and total net revenue has dropped from $225.6M in Q4 2025 to $43.8M in Q2 2026, indicating severe market disruption.
• Negative cash flow and profitability — Operating cash flow was -$10.3M in 2025 and net loss deepened to $96.3M in Q2 2026; cash and equivalents stood at $46.1M as of June 30, 2026.
• Manufacturing transition risk — Dermagraft manufacturing/distribution is suspended pending transition to a new facility, which could delay product availability and increase costs.

Outlook

Management sees signs of measured improvement but expects a slower recovery than previously anticipated. They plan to leverage their strongest long-term position with best evidence-based products. The company faces continued headwinds from Medicare policy changes and market contraction.